ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Hematologic Cancer
Lymphoma
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Charlotte, NC, USA:

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...

Enrolling
Multiple Myeloma
Biological: bb2121
Drug: Talquetamab

Phase 2

Celgene
Celgene

Charlotte, North Carolina, United States and 25 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Charlotte, North Carolina, United States and 145 other locations

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma...

Active, not recruiting
Multiple Myeloma
Myeloma
Drug: Cyclophosphamide
Drug: Bendamustine

Phase 1

Fate Therapeutics
Fate Therapeutics

Charlotte, North Carolina, United States and 13 other locations

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

AbbVie
AbbVie

Charlotte, North Carolina, United States and 40 other locations

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bisp...

Active, not recruiting
Multiple Myeloma
Drug: TNB-383B

Phase 1, Phase 2

TeneoOne

Charlotte, North Carolina, United States and 13 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Charlotte, North Carolina, United States and 211 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Charlotte, North Carolina, United States and 126 other locations

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...

Enrolling
Multiple Myeloma
Biological: BMS-986393

Phase 2

Juno Therapeutics

Charlotte, North Carolina, United States and 46 other locations

of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longe...

Enrolling
Relapsed/Refractory Multiple Myeloma
Biological: CB-011

Phase 1

Caribou Biosciences

Charlotte, North Carolina, United States and 17 other locations

and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options...

Active, not recruiting
Relapsed or Refractory Multiple Myeloma
Drug: ORIC-533

Phase 1

Oric Pharmaceuticals

Charlotte, North Carolina, United States and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems